科兴制药 (688136.SH) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.5B	1.5B	1.4B	1.3B	1.3B
Cost of Revenue	564.4M	562.0M	440.5M	367.8M	324.2M
Gross Profit	896.6M	972.1M	966.4M	891.3M	991.7M
Operating Expenses
R&D Expense	196.4M	199.6M	168.1M	344.8M	193.3M
SG&A Expense	—	—	—	—	—
General & Admin Expense	92.1M	93.7M	86.0M	86.8M	85.9M
Selling & Marketing Expense	544.4M	574.3M	596.8M	689.3M	827.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	892.0M	917.5M	903.9M	1.2B	1.1B
Cost and Expenses	1.5B	1.5B	1.3B	1.5B	1.5B
Operating Income (EBIT)	108.3M	168.1M	63.2M	(256.2M)	(138.6M)
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	108.1M	165.7M	56.9M	(260.1M)	(139.1M)
Income Tax Expense	(1.3M)	13.0M	29.9M	(64.6M)	(46.2M)
Bottom Line
Net Income	112.1M	155.6M	31.5M	(190.3M)	(90.3M)
Earnings from Cont. Ops	109.3M	152.7M	27.0M	(195.5M)	(92.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	112.1M	155.6M	31.5M	(190.3M)	(90.3M)
Per Share
Basic EPS	CN¥0.57	CN¥0.79	CN¥0.16	(CN¥0.96)	(CN¥0.45)
Diluted EPS	CN¥0.57	CN¥0.79	CN¥0.16	(CN¥0.96)	(CN¥0.45)
Revenue Per Share	CN¥7.33	CN¥7.79	CN¥7.15	CN¥6.35	CN¥6.56
Shares
Basic Shares Outstanding	199.3M	196.9M	196.8M	198.2M	200.7M
Diluted Shares Outstanding	199.3M	196.9M	196.8M	198.2M	200.7M
Profitability Metrics
EBITDA	—	272.1M	157.0M	(172.2M)	(73.6M)
D&A	—	104.0M	93.8M	84.1M	65.0M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026